



## DICE Therapeutics to Participate at Upcoming Investor Conferences

February 8, 2023

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced management will participate at the following investor conferences:

- **SVB Securities Global Biopharma Conference 2023**  
Fireside Chat: Tuesday, February 14 at 2:20 p.m. ET
- **43rd Annual Cowen Healthcare Conference**  
Dermatology Panel: Tuesday, March 7 at 12:50 p.m. ET

Live and archived webcasts of the presentations will be accessible under "News & Events" in the Investors section of the company's website for 90 days after the applicable event.

### **About DICE Therapeutics, Inc.**

DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company's DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE's lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting  $\alpha 4\beta 7$  integrin and  $\alpha V\beta 1/\alpha V\beta 6$  integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

### **Contacts:**

#### Media:

Katie Engleman, 1AB  
[katie@1abmedia.com](mailto:katie@1abmedia.com)

#### Investors:

[investors@dicetx.com](mailto:investors@dicetx.com)